- •Consistent assessment by two observers of ER and PR expression in >80% endometrial carcinomas.
- •Low ER and PR tumor expression combined is significantly associated with poor endometrial cancer-specific survival.
- •Nonetheless, tumor ER and PR status does not markedly improve mortality prediction at the individual level.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.Int. J. Cancer. 2015; 136: E359-86
- Refining the definition of low-risk endometrial cancer: improving value.Gynecol. Oncol. 2016; 141: 189-190
- Current status of molecular biomarkers in endometrial cancer.Curr. Oncol. Rep. 2014; 16: 403
- Contemporary management of endometrial cancer.Lancet. 2012; 379: 1352-1360
- Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts.Clin. Cancer Res. 2016; 22: 4215-4224
- A clinically applicable molecular-based classification for endometrial cancers.Br. J. Cancer. 2015; 113: 299-310
- Progesterone action in breast, uterine, and ovarian cancers.J. Mol. Endocrinol. 2015; 54: R31-53
- Distribution of estrogen and progesterone receptors isoforms in endometrial cancer.Diagn. Pathol. 2014; 9: 77
- Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: a Canadian high risk endometrial cancer consortium (CHREC) study.Gynecol. Oncol. 2016; 141: 559-563
- Development of an evidence-based approach to external quality assurance for breast cancer hormone receptor immunohistochemistry: comparison of reference values.Arch. Pathol. Lab. Med. 2011; 135: 874-881
- Quality assurance in immunohistochemistry – an update.Pathology. 2010; 42 (S11-S2)
- Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.Eur. J. Cancer. 2013; 49: 3431-3441
- Histological and immunohistochemical profiles predict lymph node status in women with low-intermediate risk endometrial cancer.Gynecol. Oncol. 2013; 130: 457-462
- Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.Gynecol. Oncol. 2013; 130: 463-469
- Endometrial endometrioid carcinoma metastases show decreased ER-alpha and PR-A expression compared to matched primary tumors.PLoS One. 2015; 10e0134969
- Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer.Gynecol. Oncol. 2016; 141: 312-317
- Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions.Eur. J. Cancer. 2014; 50: 3003-3010
- Endometrial cancer risk factors, hormone receptors, and mortality prediction.Cancer Epidemiol. Biomark. Prev. 2017; 26: 727-735
- Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.J. Clin. Oncol. 2014; 32: 90-100
- Prognostic and predictive factors in breast cancer by immunohistochemical analysis.Mod. Pathol. 1998; 11: 155-168
- Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.Stat. Med. 1996; 15: 361-387
- Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma.Clin. Cancer Res. 2013; 19: 1094-1105
- Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.World J. Surg. Oncol. 2015; 13: 208
- Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.Gynecol. Oncol. 2009; 112: 537-542
- Progesterone receptor isoforms as a prognostic marker in human endometrial carcinoma.Cancer Sci. 2006; 97: 1308-1314
- Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma.Am. J. Surg. Pathol. 2013; 37: 874-881
- Bokhman redux: endometrial cancer “types” in the 21st century.Gynecol. Oncol. 2017; 144: 243-249
- Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma.Cancer Sci. 2012; 103: 926-932
- Coordinate patterns of estrogen receptor, progesterone receptor, and Wilms tumor 1 expression in the histopathologic distinction of ovarian from endometrial serous adenocarcinomas.Ann. Diagn. Pathol. 2013; 17: 430-433
- ER+/PR+/TFF3+/IMP3- immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: a study of 401 cases.Histopathology. 2013; 62: 976-985
- Expression of estrogen receptor-alpha as a prognostic factor in patients with uterine serous carcinoma.Int. J. Gynecol. Cancer. 2014; 24: 102-106
- Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – a pooled analysis of PORTEC 1 and 2 trials.Eur. J. Cancer. 2015; 51: 1742-1750